DoorDash Q2 Revenue Jumps 36% as Orders and DashPass Growth Drive Results 
Siemens Energy Q3 Profit Beats Forecast as AI-Driven Power Demand Fuels Growth 
Meta Ordered to Pay $567M Over Child Safety Violations in New Mexico 
Infineon Raises 2026 Revenue Outlook as AI Data Center Demand Fuels Record Quarterly Sales 
AMP Shares Surge 13% After Strong Profit and A$150 Million Buyback 
Alibaba Plans Revenue-Sharing Model for Qwen3.8-Max AI Commercial Users 
SoftBank Q1 Profit Beats Forecast as Intel Rally and OpenAI Investments Boost Returns 
Cloudflare Stock Jumps 15% as Earnings Beat Estimates, 2026 Outlook Raised 
Qantas Shares Climb as Long-Haul Pilot Deal Eases Strike Concerns 
Moderna Wins FDA Approval for mFLUSIVA mRNA Flu Vaccine for Adults 50+ 
Sinopec Boosts Russian ESPO Oil Purchases as Middle East Supply Tightens 
UK AI Security Tests Reveal Anthropic and OpenAI Agents Attempted Unauthorized Actions 
Novo Nordisk Raises 2025 Outlook Despite Wegovy Pill Miss and CagriSema Setback 
SpaceX Targets Starship Flight 14 With First V3 Starlink Satellite Launch 
Alphabet Stock Slides as Google AI Pioneer Jeff Dean Exits to Launch Discovery Loop 
DHL Q2 Profit Jumps 24% as Express Business Drives Growth 
Nvidia to Invest Up to $3 Billion in Blackstone-Backed Lancium 
WALTHAM, Mass., March 06, 2018 -- Eloxx Pharmaceuticals, Inc. (“Eloxx”), (ELOX) a clinical-stage biopharmaceutical company developing novel read-through drug candidates that are designed to treat rare and ultra-rare premature stop codon diseases, today announced that Chairman and Chief Executive Officer, Robert E. Ward, will present at the Cowen and Company 38th Annual Health Care Conference on Monday, March 12, 2018 at 1:30 p.m. EST at the Boston Marriott Copley Place.
A live audio webcast witll be available on the “Events & Presentations” section of the Company's investor website at www.radiuspharm.com, where a replay will also be available following the presentation.
About Eloxx Pharmaceuticals
Eloxx Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company developing novel RNA-modulating drug candidates that are designed to treat rare and ultra-rare premature stop codon diseases. Premature stop codons are point mutations that disrupt protein synthesis from messenger RNA. As a consequence, patients with premature stop codon diseases have reduced or eliminated protein production from the mutation bearing allele accounting for some of the most severe phenotypes in these genetic diseases. These premature stop codons have been identified in over 2,000 rare and ultra-rare diseases. Read-through therapeutic development is focused on extending mRNA half-life and increasing protein synthesis by enabling the cytoplasmic ribosome to read through premature stop codons to produce full-length proteins. Eloxx’s lead product candidate, ELX-02, is a small molecule drug candidate designed to restore production of full-length functional proteins. ELX-02 is in the early stages of clinical development focusing on cystic fibrosis and cystinosis. ELX-02 is an investigational drug that has not been approved by any global regulatory body. Eloxx is headquartered in Waltham, MA. with R&D operations in Rehovot, Israel.
Contact:
Barbara Ryan
203-274-2825
[email protected]
